Decreased expression of the Nkx2.8 gene correlates with tumor progression and a poor prognosis in HCC cancer

Cancer Cell International

Volumn 14, Issue 1, 2014, Pages

  Qu, Lei ^a   Deng, Biao ^a   Zeng, Yue ^a   Cao, Zhongwei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cell proliferation; Clinicopathological factors; HCC; Nkx2.8; Prognosis

Indexed keywords

MESSENGER RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX2.8; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL LINE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCHEMISTRY; LIVER CELL CARCINOMA; MALE; MTT ASSAY; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR GROWTH; CANCER GROWTH; CANCER SURGERY; CELLULAR DISTRIBUTION; CLONOGENIC ASSAY; CYTOPLASM; IMMUNOHISTOCHEMISTRY; LIVER RESECTION; QUANTITATIVE ANALYSIS; WESTERN BLOTTING;

EID: 84899918376     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-14-28     Document Type: Article

References (23)

1. Shiraha H, Yamamoto K, Namba M. Human hepatocyte carcinogenesis (review). Int J Oncol 2013, 42:1133-1138. 3622653, 23426905.
2. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, Khin MW, Koo WH, . Asian Oncology Summit Management of hepatocellular carcinoma in Asia: consensus statement from the Asian oncology summit 2009. Lancet Oncol 2009, 10:1111-1118. 10.1016/S1470-2045(09)70241-4, 19880065, Asian Oncology Summit.
3. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J, . EASL Panel of Experts on HCC Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430. 10.1016/S0168-8278(01)00130-1, 11592607, EASL Panel of Experts on HCC.
4. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16. 10.1053/j.gastro.2004.09.011, 15508102.
5. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003, 9:416-423. 10.1038/nm843, 12640447.
6. Sun BS, Dong QZ, Ye QH, Sun HJ, Jia HL, Zhu XQ, Liu DY, Chen J, Xue Q, Zhou HJ, Ren N, Qin LX. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology 2008, 48:1834-1842. 10.1002/hep.22531, 18972404.
7. Su L, David M. Distinct mechanisms of STAT phosphorylation via the interferon-alpha/beta receptor. Selective inhibition of STAT3 and STAT5 by piceatannol. J Biol Chem 2000, 275:12661-12666. 10.1074/jbc.275.17.12661, 10777558.
8. Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C, Clergue F, Poupon R, Barbu V, Rosmorduc O. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005, 41:307-314. 10.1002/hep.20538, 15660382.
9. Yu C, Zhang Z, Liao W, Zhao X, Liu L, Wu Y, Liu Z, Li Y, Zhong Y, Chen K, Li J, Zhou F, Song L. The tumor-suppressor gene Nkx2.8 suppresses bladder cancer proliferation through upregulation of FOXO3a and inhibition of the MEK/ERK signaling pathway. Carcinogenesis 2012, 33:678-686. 10.1093/carcin/bgr321, 22223847.
10. Lin C, Song L, Gong H, Liu A, Lin X, Wu J, Li M, Li J. Nkx2-8 downregulation promotes angiogenesis and activates NF-kappaB in esophageal cancer. Cancer Res 2013, 73:3638-3648. 10.1158/0008-5472.CAN-12-4028, 23604637.
11. Harris T, Pan Q, Sironi J, Lutz D, Tian J, Sapkar J, Perez-Soler R, Keller S, Locker J. Both gene amplification and allelic loss occur at 14q13.3 in lung cancer. Clin Cancer Res 2011, 17:690-699. 10.1158/1078-0432.CCR-10-1892, 3041868, 21148747.
12. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
13. Seeff LB, Hoofnagle JH. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene 2006, 25:3771-3777. 10.1038/sj.onc.1209560, 16799618.
14. Kwon OS, Jung YK, Kim YS, Kim SG, Kim YS, Lee JI, Lee JW, Kim YS, Chun BC, Kim JH. Effect of alcohol on the development of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis: a cross-sectional case-control study. Korean J Hepatol 2010, 16:308-314. 10.3350/kjhep.2010.16.3.308, 3304590, 20924214.
15. Long XD, Yao JG, Zeng Z, Ma Y, Huang XY, Wei ZH, Liu M, Zhang JJ, Xue F, Zhai B, Xia Q. Polymorphisms in the coding region of X-ray repair complementing group 4 and aflatoxin B1-related hepatocellular carcinoma. Hepatology 2013, 58:171-181. 10.1002/hep.26311, 23390017.
16. Blanpain C. Tracing the cellular origin of cancer. Nat Cell Biol 2013, 15:126-134. 10.1038/ncb2657, 23334500.
17. Lapouge G, Youssef KK, Vokaer B, Achouri Y, Michaux C, Sotiropoulou PA, Blanpain C. Identifying the cellular origin of squamous skin tumors. Proc Natl Acad Sci U S A 2011, 108:7431-7436. 10.1073/pnas.1012720108, 3088632, 21502497.
18. Zhu XC, Dong QZ, Zhang XF, Deng B, Jia HL, Ye QH, Qin LX, Wu XZ. microRNA-29a suppresses cell proliferation by targeting SPARC in hepatocellular carcinoma. Int J Mol Med 2012, 30:1321-1326.
19. Zhu HT, Dong QZ, Sheng YY, Wei JW, Wang G, Zhou HJ, Ren N, Jia HL, Ye QH, Qin LX. MicroRNA-29a-5p is a novel predictor for early recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. PLoS One 2012, 7:e52393. 10.1371/journal.pone.0052393, 3527523, 23285022.
20. Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, Wang N, Niu Y, Wu Z, Zhou J, Qiu SJ, Shi YH, Yu B, Tang N, Chu W, Wang M, Wu J, Zhang Z, Yang S, Gu J, Wang H, Qin W. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol 2012, 13:817-826. 10.1016/S1470-2045(12)70233-4, 22738799.
21. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012, 55:483-490. 10.1002/hep.24703, 3914762, 21953299.
22. Apergis GA, Crawford N, Ghosh D, Steppan CM, Vorachek WR, Wen P, Locker J. A novel nk-2-related transcription factor associated with human fetal liver and hepatocellular carcinoma. J Biol Chem 1998, 273:2917-2925. 10.1074/jbc.273.5.2917, 9446603.
23. Hsu DS, Acharya CR, Balakumaran BS, Riedel RF, Kim MK, Stevenson M, Tuchman S, Mukherjee S, Barry W, Dressman HK, Nevins JR, Powers S, Mu D, Potti A. Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. Proc Natl Acad Sci U S A 2009, 106:5312-5317. 10.1073/pnas.0900827106, 2664027, 19279207.